Literature DB >> 33179141

Identification of immune-related genes with prognostic significance in the microenvironment of cutaneous melanoma.

Yan Qu1, Shuqing Zhang2, Yan Zhang3, Xien Feng4, Fengjuan Wang5.   

Abstract

Cutaneous melanoma is one of the most aggressive cancers characterized by increasing incidence and mortality. In recent years, the emergence of immunotherapy has greatly raised the survival rate of patients suffering from cutaneous melanoma, yet some sufferers remain to have poor outcomes after treatment mainly due to the tumor microenvironment (TME). In this study, cutaneous melanoma-associated TME was systematically analyzed using the ESTIMATE algorithm based on the gene transcriptome data obtained from the TCGA database. Totally, 471 patients were included and 553 TME-related genes were screened. Afterwards, a 3-gene signature-based model (CLEC4A, GBP4, KIR2DL4) was constructed via univariate Cox, LASSO, and multivariate Cox regression analyses. To validate the validity of this model, ROC analysis was conducted, and the model was further validated to be an independent prognostic biomarker through univariate and multivariate regression analyses. Finally, the three genes in the model were studied by GSEA and GSVA for their biological significance. We found that the three genes could promote cancer immune response predominantly through affecting immune-related pathways such as antigen processing and presentation, and they may help tumor cells in escaping from surveillance of the immune system when their expression levels were decreased. Additionally, we as well discovered that the expression of the three genes was significantly and positively correlated with the infiltration of related immune cells, but negatively associated with tumor purity. Overall, this study comprehensively analyzed the TME of cutaneous melanoma, identified related biomarkers, and discovered their association with immune system.

Entities:  

Keywords:  Cutaneous melanoma; Immunity; Prognosis; Tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33179141     DOI: 10.1007/s00428-020-02948-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  53 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  Matias E Valsecchi
Journal:  N Engl J Med       Date:  2015-09-24       Impact factor: 91.245

Review 3.  Tumor microenvironment: Sanctuary of the devil.

Authors:  Lanlan Hui; Ye Chen
Journal:  Cancer Lett       Date:  2015-08-11       Impact factor: 8.679

Review 4.  Accessories to the crime: functions of cells recruited to the tumor microenvironment.

Authors:  Douglas Hanahan; Lisa M Coussens
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 5.  Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.

Authors:  Grant M Fischer; Y N Vashisht Gopal; Jennifer L McQuade; Weiyi Peng; Ralph J DeBerardinis; Michael A Davies
Journal:  Pigment Cell Melanoma Res       Date:  2017-11-02       Impact factor: 4.693

Review 6.  Therapeutic vaccines for cancer: an overview of clinical trials.

Authors:  Ignacio Melero; Gustav Gaudernack; Winald Gerritsen; Christoph Huber; Giorgio Parmiani; Suzy Scholl; Nicholas Thatcher; John Wagstaff; Christoph Zielinski; Ian Faulkner; Håkan Mellstedt
Journal:  Nat Rev Clin Oncol       Date:  2014-07-08       Impact factor: 66.675

7.  Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.

Authors:  L Cabel; F Riva; V Servois; A Livartowski; C Daniel; A Rampanou; O Lantz; E Romano; M Milder; B Buecher; S Piperno-Neumann; V Bernard; S Baulande; I Bieche; J Y Pierga; C Proudhon; F-C Bidard
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

8.  The immune score as a new possible approach for the classification of cancer.

Authors:  Jérôme Galon; Franck Pagès; Francesco M Marincola; Magdalena Thurin; Giorgio Trinchieri; Bernard A Fox; Thomas F Gajewski; Paolo A Ascierto
Journal:  J Transl Med       Date:  2012-01-03       Impact factor: 5.531

Review 9.  Human Tumor Antigens and Cancer Immunotherapy.

Authors:  Nathalie Vigneron
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

10.  Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.

Authors:  Nadeem Riaz; Jonathan J Havel; Sviatoslav M Kendall; Vladimir Makarov; Logan A Walsh; Alexis Desrichard; Nils Weinhold; Timothy A Chan
Journal:  Nat Genet       Date:  2016-09-26       Impact factor: 38.330

View more
  4 in total

1.  Pancreatic adenocarcinoma associated immune-gene signature as a novo risk factor for clinical prognosis prediction in hepatocellular carcinoma.

Authors:  Lei Dai; Joseph Mugaanyi; Xingchen Cai; Caide Lu; Changjiang Lu
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

2.  Identification of a novel tumour microenvironment-based prognostic biomarker in skin cutaneous melanoma.

Authors:  Rong-Hua Yang; Bo Liang; Jie-Hua Li; Xiao-Bing Pi; Kai Yu; Shi-Jian Xiang; Ning Gu; Xiao-Dong Chen; Si-Tong Zhou
Journal:  J Cell Mol Med       Date:  2021-11-10       Impact factor: 5.310

3.  Development and Validation of a Novel Survival Model for Cutaneous Melanoma Based on Necroptosis-Related Genes.

Authors:  Zehao Niu; Xin Wang; Yujian Xu; Yan Li; Xiaojing Gong; Quan Zeng; Biao Zhang; Jiafei Xi; Xuetao Pei; Wen Yue; Yan Han
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

4.  Esophageal Cancer Associated Immune Genes as Biomarkers for Predicting Outcome in Upper Gastrointestinal Tumors.

Authors:  Chuanhui Zhu; Qianqian Xia; Bin Gu; Mengjing Cui; Xing Zhang; Wenjing Yan; Dan Meng; Siyuan Shen; Shuqian Xie; Xueliang Li; Hua Jin; Shizhi Wang
Journal:  Front Genet       Date:  2021-07-19       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.